Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells

<p>Graphical abstract. A multi-omics analysis of the glioblastoma tumor microenvironment revealed that biglycan, predominantly expressed by inflammatory BTICs, drives tumor growth. The graphics were generated with Biorender.com.</p>

Tallennettuna:

Bibliografiset tiedot
Päätekijä:	Reza Mirzaei (15306062) (author)
Muut tekijät:	Charlotte D'Mello (15306065) (author), Marina Liu (15306068) (author), Ana Nikolic (15306071) (author), Mehul Kumar (15306074) (author), Frank Visser (15306077) (author), Pinaki Bose (15306080) (author), Marco Gallo (8808401) (author), V. Wee Yong (15306083) (author)
Julkaistu:	2025
Aiheet:	Cancer Tumor Biology Molecular and Cellular Biology CNS Cancers Gliomas, Glioblastomas Stem Cell Biology Cancer stem cells Tumor Heterogeneity
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
Tekijä: Reza Mirzaei (15306062)
Julkaistu: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
Tekijä: Reza Mirzaei (15306062)
Julkaistu: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Tekijä: Michael Kilian (16697663)
Julkaistu: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Tekijä: Michael Kilian (16697663)
Julkaistu: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Tekijä: Michael Kilian (16697663)
Julkaistu: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Tekijä: Defne Bayik (14961098)
Julkaistu: (2025)

Table S1 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Table S2 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Table S3 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Table S4 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Table S5 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Table S6 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Table S7 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Tekijä: Lanpeng Chen (16918293)
Julkaistu: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
Tekijä: Isha Mondal (16721699)
Julkaistu: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Data Sheet 1_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.csv
Tekijä: Zhongyi Zhang (219440)
Julkaistu: (2025)

Data Sheet 2_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.pdf
Tekijä: Zhongyi Zhang (219440)
Julkaistu: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Tekijä: Francesca Orzan (15055579)
Julkaistu: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Tekijä: Francesca Orzan (15055579)
Julkaistu: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Tekijä: Francesca Orzan (15055579)
Julkaistu: (2025)

Graphical abstract.
Tekijä: Ji-Xin Zhao (22056386)
Julkaistu: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Tekijä: Sied Kebir (15048732)
Julkaistu: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Tekijä: Sied Kebir (15048732)
Julkaistu: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Tekijä: Sied Kebir (15048732)
Julkaistu: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Tekijä: Sied Kebir (15048732)
Julkaistu: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Tekijä: Sied Kebir (15048732)
Julkaistu: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tekijä: Joseph Toker (15399882)
Julkaistu: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
Tekijä: Takeru Oka (15386810)
Julkaistu: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
Tekijä: Takeru Oka (15386810)
Julkaistu: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Tekijä: Qingsheng Xu (17078830)
Julkaistu: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Tekijä: Qingsheng Xu (17078830)
Julkaistu: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nn9oarh9bt8hfb1o08jj6pid7g